The basic principle of the APC-resistance test; Modification of this test in which the patient's plasma is diluted in FV-deficient plasma; The FV:Q allele.DahlbackBjornEBSCO_AspLancetDahlback B (1996) Are we ready for factor V Leiden screening? Lancet 347:1346-7...
Testing The diagnosis of Factor V Leiden requires the APC resis- tance assay, a coagulation screening test, or DNA analysis of F5, the gene encoding Factor V, to identify the Leiden mutation, a specific G-to-A substitution at nucleotide 1691 that predicts a single-amino acid replacement (R...
Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997; 227: 1305–1307. Article Google Scholar Gregg JP, Yamane A, Grody WW . The prevalence of the factor V Leiden mutation in four distinct American ethnic populations. Am J...
The factor V Leiden (FVL) mutation is associated with vascular complications in pregnancy, and routine screening of all pregnant women has been suggested. We did a prospective, unselected study in 967 pregnant women to evaluate the cost-effectiveness of screening all women, or only those with a...
This new assay for Factor V-Leiden can be easily used in any coagulation laboratory, is performed as a single test, and is quantitative. This assay has a high robustness, is accurate and presents a good intra- (<3%) and inter-assay (<5%) variability. It contributes solving most of the...
Factor V Leiden in blood donors in Baghdad (Iraq) The assessment for activated protein C resistance is initiated by performance of a screening test using factor V-deficient plasma as a diluent for the patient plasma. Activated protein C resistance, the factor V Leiden mutation, and a laboratory...
The test was performed using a kit (Chromogenix, Sweden) on a centrifugal autoanalyzer (Instrumentation Laboratory, UK) essentially according to the manufacturer's instructions. Results were expressed as ratios of two APTTs performed in the presence and absence of APC. Screening for factor V Leiden...
FV/PT 2.11.2 Prenatal testing and newborn screening. As discussed in the ACMG Consensus Statement on Factor V Lei- den Mutation Testing,1 because the pregnancy complications associated (i.e., in utero thrombosis) with possessing the factor V Leiden mutation are generally maternal rather than ...
Inhibitor Screening Nonspecific inhibitors commonly used for screening include lupus anticoagulant and ELISA testing against β-2 glycoprotein and cardiolipin antibodies, which may be elevated in acquired factor V deficiency. The Bethesda assay, measuring inhibitors against a specific factor in the blood, ...
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein.